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Background: Microalbuminuria is a marker of early kidney disease and high cardiovascular risk in various populations,
including HIV positive patients. However, the diagnostic value of qualitative (dipstick) proteinuria and the burden of
microalbuminuria in HIV positive patients living in sub-Saharan Africa are relatively unclear.
Methods: In a cross-sectional study, 235 HIV- positive outpatients were screened for proteinuria in 3 HIV-clinics in Bukavu.
A spot urine sample from each subject was tested both by a dipstick and albumin-creatinine-ratio (ACR) assay. The
performance of dipstick proteinuria exceeding 1+ was compared with that of microalbuminuria (≥30 mg/g creatinine).
Results: The prevalence of microalbuminuria and dipstick proteinuria ≥ (1+), ≥ (2+) and ≥ (3+) was 11%, 41%, 3.5% and
0.7%, respectively.
Compared to microalbuminuria, the dipstick (proteinuria of 1+ or greater) had an overall sensitivity of 60% and a
specificity of 61%. The positive predictive value was 15.4% and the negative predictive value 92.8%.
Conclusion: Proteinuria is highly prevalent in HIV positive patients. The limited sensitivity and specificity of the dipstick to
detect significant microalbuminuria make it unattractive as a screening tool in HIV positive patients.
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The prevalence of chronic kidney disease (CKD) is high
in the African HIV infected population [1,2] where late
referral to hospital and scarce possibilities of renal re-
placement therapy are well known. The early detection
of CKD would provide the opportunity to implement
strategies known to slow CKD progression [3,4]. Thus,
the identification of overt proteinuria or even microalbu-
minuria, might be an important tool for the early detec-
tion of CKD in HIV-infected individuals [5,6]. The* Correspondence: masimax2003@yahoo.fr
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article, unless otherwise stated.Infectious Diseases Society of America (IDSA) guidelines
on the management of chronic kidney disease in HIV-
positive patients recommend the use of a urine dipstick,
with a threshold for detection of renal disease at 1+ pro-
teinuria. When dipstick is ≥ 1, a quantification of protein-
uria is recommended. Currently, this relies on the albumin/
creatinine ratio (ACR) measured on a spot of urine [7,8].
However, in many emerging countries, the dipstick remains
the only method used for the evaluation of proteinuria.
Nevertheless, it is recognized that dipsticks may have poor
sensitivity in detecting low-grade proteinuria [9].
The purpose of the current study was to evaluate the
prevalence of proteinuria in HIV-positive patients and to
assess the diagnostic value of urinary dipstick as screen-
ing test for proteinuria compared with the albumin/cre-
atinine ratio (ACR).ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Written informed consent for participation in the study
was obtained from participants.
A cross-sectional survey was conducted in March and
April 2012 in 3 outpatient HIV-clinics in Bukavu, the
main town in the eastern rural part of the Democratic
Republic of Congo (DRC).
Two hundred and sixty consecutive HIV-1 positive
adults (≥18 years) who routinely attended one of the
clinics during the survey period were screened.
Single spot urine specimens were collected in the morn-
ing. Urine samples containing blood (1+ or greater), white
blood cells (1+ or greater) and/ or nitrites were excluded.
This left 235 subjects in whom, both a urine dipstick test
and a urine albumin to creatinine ratio measurement were
performed (ACR). The results of urine dipstick (Multistix 8
SG®, Siemens Healthcare Diagnostics, France) were read as
either negative (<30 mg/dl) or positive at 1+, 2+, 3+ or
greater, corresponding approximately to protein concentra-
tions of 30, 100 mg/dl , 300 and ≥ 2000 mg/dl. ACR was
performed using the DCA VantageTM analyzer (Siemens
Healthcare Diagnostics Pyt Ltd., 885 Mountain Highway,
Australia), utilizing an immunoassay method for Albumin.
Microalbuminuria was defined by a urinary albumin-to-
creatinine ratio (ACR) 30–299 mg/g and macroalbuminuria
by an ACR > 300 mg/g. The diagnostic value (sensitivity,
specificity, positive predictive value, negative predictive
value) of dipstick ≥ 1+ and ≥ 2 + to detect micro or macro
albuminuria was thus assessed.
Statistical tools
The processing and data analysis were performed using
SPPS software Windows version 18.0 and MedCalc 9.2.1.0.
Quantitative albuminuria expressed as ACR was subdi-
vided into three sub-groups: <30 mg/g (normoalbumi-
nuria), 30 to 299 mg/g (microalbuminuria) and ≥ 300 mg/g
(macroalbuminuria), and compared with the respective re-
sults of the dipstick on the same sample.
The diagnostic value (sensitivity, specificity, positive
predictive value, negative predictive value) of the
dipstick 1+ or greater (>30 mg/dl) was thus studied.
The cutoff of 1+ was chosen on the basis of IDSA’s
recommendations.
Ethical issues
Permission obtained from the Ethics Committee of the
school of Medicine of the Catholic University of Bukavu
(Commission Institutionnelle d’Ethique, 09 juin 2012).
Results
A total of 260 patients were contacted. Twenty-five had
to be excluded because of hematuria (n = 12), detection
of nitrites in urine (n = 8) or leucocyturia (n = 5). The 25excluded patients had demographic characteristics simi-
lar to those of the 235 included patients.
A total of 235 patients were thus included, of whom
179 (76.2%) were on antiretroviral therapy. Baseline data
are provided in Tables 1, 2 and 3. All patients were African.
Median age was 40 years (IQR 18–74) and 73.2% were
women.
Median CD4 cell count was 480 cells /mm3 (IQR 10–
1202). The overall prevalence of proteinuria according
to ACR was 10.6% (95% CI 6.67- 14.53), 8.9% for micro-
albuminuria (ACR 30–300 mg/g) and 1.7% for macroal-
buminuria (ACR >300 mg/g). In contrast, the prevalence
of dipstick urine protein (1+), (2+) and (3+) were 37%,
3.4% and 0.9%, respectively.
Regarding the intensity of proteinuria, no difference
was observed between the groups receiving antiretroviral
versus ART naive patients.
The 235 paired dipstick and quantitative results are
displayed in Table 4.
Seventy-six (36.2%) of 210 patients with urine ACR <
30 mg/g had a positive urine dipstick results (false-
positive result ≥ 1+). Furthermore, 10 (47.6%) of 21 pa-
tients with abnormal low-level albuminuria (UACR 30
to 299 mg/g) had negative urine dipstick results (false-
negative result: 1+).
In comparison with ACR > 30 mg/g, urine dipstick had
an overall sensitivity and specificity of 60% and 61%, re-
spectively. At a prevalence of proteinuria of 10.6%, the
positive predictive value of positive urine dipstick for
ACR >30 mg/g was 15.4% and the negative predictive
value 92.8%.
Discussion
The purposes of this study were to determine the preva-
lence of microalbuminuria in an HIV-infected clinic
population in DRC and the performance of the dipstick
urine test compared to the ACR. Approximately three
quarter of the subjects were women, consistent with
other data showing a feminization of HIV infection, par-
ticularly in Africa [10,11].
In the present study, the prevalence of proteinuria with
dipstick test (≥1+) was 41.3%. Cohort studies suggest that
approximately 30% of HIV-positive individuals have pro-
teinuria (≥1+). Similar results are reported by Fabian et al.
in South Africa (44%) [12] and Jao et al. in Cameroon
(39%) [13]. However, Struik et al. [14] and Longo et al. [15]
reported a lower prevalence, 23 and 21% respectively. Fur-
thermore, the prevalence of quantitative proteinuria defined
as ACR ≥ 30 mg/g was 10.6%. This prevalence is similar to
that of earlier reports varying from 6% to 30% in the HIV-
infected, which is three to five times higher than in the
general population [16-19]. Differences in methodological
approach and in clinical profile of patients could probably
explain the variability of results between studies.
Table 1 General characteristics of studied population
Variables Whole group HAART subjects ART naive subjects p
n = 235 n = 179 n = 56
Female, % 172 (73,2) 127 (54) 45 (19,1) 0,0001
Age (years, median) 40,0 ± 10,7 42,3 ± 10,6 35 ± 9,7 < 0,0001
Family history of:
- DM 48 (20,4) 41 (17,4) 7 (3) 0,06
- Hypertension 72 (30,6) 54 (23,0) 18 (7,7) 0,28
- Obesity 50 (21,3) 39 (16,6) 11 (4,7) 0,61
- CKD 22 (9,4) 15 (6,4) 7 (3,0) 0,49
Comorbidities
- DM 4 (1,7) 4 (1,7) 0 (0) 0,597
- Hypertension 110(46,8) 87 (37,0) 23 (9,8) 0,02
Level of education < 6 years 113 (48,9) 79 (34,2) 34 (14,7) 0,05
Marital status:
- Married 104 (55,7) 78 (43) 26 (12,8) 0,01
- widow 131 (55,7) 101 (43) 30 (12,8) 0,005
History of smoking 28 (11,9) 21 (8,9) 7 (3) 0,73
History of alcohol consumption 107 (45,5) 82 (34,9) 25 (10,6) 0,036
History of medicinal plants use 29 (12,3) 19 (8,1) 10 (4,3) 0,69
History of NSAIDS use 49 (20,9) 39 (16,6) 10 (4,3) 0,62
Data are expressed as absolute or relative frequencies or mean plus the standard deviation (SD) as appropriate.
Table 2 Clinical characteristics of subjects
Variables Whole group HAART subjects ART naive subjects p
n = 235 n = 179 n = 56
Known HIV infection duration (years) 4,7 ± 3,2 5,3 ± 3,04 2,8 ± 2,9 <0,0001
Duration of HAART (months) NA 46,2 ± 30,08 NA
WHO stage for HIV clinical disease:
- Stage 1 25 (10,6) 12 (5,1) 13 (5,5) 0,39
- Stage 2 53 (22,6) 21 (8,9) 32 (13,6) 0,93
- Stage 3 140 (59,6) 129 (54,9) 11 (4,7) 0,0039
- Stage 4 17 (7,2) 17 (7,2) 0 <0,0001
Body mass index (kg/m2) 22,3 ± 3,8 22,5 ± 3,9 21,7 ± 3,4 0,198
SBP (mmHg) 118,82 ± 20,89 120,58 ± 21,7 113,2 ± 16,7 0,023
DBP (mmHg) 77,7 ± 14,02 79,8 ± 14,7 71,8 ± 11,6 0,0002
HAART regimen:
AZT + 3TC + NVP NA 164 (94,8) NA
d4T + 3TC + NVP NA 3 (1,6) NA
ABC + DDI + Lp/r NA 9 (5) NA
TDF + 3TC + EFV NA 3 (1,6) NA
HTA = hypertension; BMC = body mass index; SBP = Systolic blood pressure; DBP = diastolic blood pressure; CKD = chronic kidney disease; HAART: Highly active
antiretroviral therapy. NA: not applicable; d4T: stavudine, 3TC: lamivudine, NVP: nevirapine, ABC: abacavir, DDI: didanosine, Lp/r : lopinavir/ritonavir, EFV: efavirenz,
TDF: tenofovir.
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Table 3 Biological characteristics of subjects
Variable Whole group HAART group ART naïve group p
Fasting glycaemia 103,5 ± 14,4 104,2 ± 15,1 100,3 ± 10,6 0,27
Hemoglobin 13,3 ± 2,0 13,5 ± 1,9 12,7 ± 2,2 0,01
HBs Ag positive 5 (1,9) 5 (2,1) 0 (0) 0,44
Anti HCV positive 3 (1,2) 1 (0,4) 2(0,9) <0,0001
CD4 (cells/mm3 increment):
- < 200 22 (10,7) 14 (6,8) 8 (3,9) 0,50
- 200-499 96 (46,8) 80 (39) 16 (7,8) 0,034
- > 500 87 (42,4) 66 (32,2) 21 (10,2) 0,089
Variables are absolute numbers and relative frequencies or means plus the standard deviation (SD) as appropriate. CD4: cluster of differentiation.
Masimango et al. BMC Nephrology 2014, 15:146 Page 4 of 5
http://www.biomedcentral.com/1471-2369/15/146Although, this study did not address the specific
causes of proteinuria in individual subjects, it is likely
that proteinuria is related to HIV itself. Experimental
studies demonstrate a direct impact of viral components
(gp120, TAT) on the endothelium, as they lead to the ex-
pression of adhesion molecules (intercellular adhesion
molecule [ICAM], E-selectin), a prothrombotic state
(increase of von Willebrand factor, plasminogen activator
inhibitor-[PAI-]1, tissue plasminogen activator [t-PA], tissue
factor). In addition, soluble adhesion molecules (selectin,
ICAM) were found to be increased in HIV-infected persons
[20]. HIV-associated nephropathy (HIVAN) is the com-
monest biopsy finding among patients with HIV infection
who present with proteinuria. Han et al. reported that 25%
of naïve HIV-positive black patients (without hypertension,
diabetes and with serum creatinine < 250 μmol/L), have
microalbuminuria, and that HIVAN was found in 86%
of the subset of such patients with persistent micro
albuminuria [19].
The results of our study suggest that the urine dipstick
may not be an adequate tool for screening for protein-
uria in HIV-positive patients. As a screening test, the
sensitivity (60%) and specificity (61%) of a single dipstick
is poor. In fact, at lower levels of proteinuria (30 to
299 mg/g), a threshold of 1+ dipstick had a false-negative
rate of 47.6%. Therefore, nearly 1 in 2 patients with protein-
uria in this range may not be recognized and may have de-
layed workup and treatment. In addition, the proportion of
false positives was 36%. Consequently, one to 3 patientsTable 4 Comparison between the dipstick and the ACR in
235 patients
A/C ratio (mg/g)
Urine dipstick <30 30-299 ≥ 300 Total
n = 210 n = 21 n = 4 n = 235
0 128 10 0 138
1+ 76 10 1 87
≥ 2+ 6 1 3 10
(*) The numbers with gray shading correspond to false-positive dipstick results.
The numbers highlighted in orange are false-negative ones.with positive dipstick (1+) could be falsely considered to be
at high cardiovascular and kidney risk.
Several studies reported the poor sensitivity of dipstick
testing to identify early renal disease in HIV-population
[9], hypertensive [21] and diabetic patients [22]. A recent
study has demonstrated that the sensitivity of dipstick
test, may be affected by urinary concentration [9]. In
addition, dipstick tests may miss about one out of five
people with kidney disease, and positive dipstick test re-
sults for proteinuria may have to be confirmed by other
laboratory tests [23]. In fact, in a study of 166 HIV-
infected persons who underwent both a urine dipstick
and a spot urine protein-to-creatinine ratio within a 48-
hour period, 21% of those with low but overt proteinuria
(300 to 900 mg/g creatinine) were not detected by urine
dipstick. So, in individuals at renal risk, such as HIV +
patients, the search for microalbuminuria is recom-
mended when the dipstick is negative. Furthermore, the
recent Kidney Disease Initiative and Global Outcome
(KDIGO) CKD Guidelines recommend, in individuals
with proteinuria by dipstick, to perform confirmatory
protein quantification within 3 months [24]. Defining
proteinuria as a positive urine dipstick test on two occa-
sions [25] could have reduced the false positive rate in
our study, but probably at the expense of an even higher
false negative rate.
Conclusion
Strengths of the study
Because of the high prevalence of proteinuria, early
screening efforts should be encouraged in HIV-patients
both before and under antiretroviral treatment. Based on
the accuracy of the semi-quantitative urine dipstick, the
KDIGO CKD Guidelines suggest the use of either a spot
protein-to-creatinine or spot albumin-to-creatinine ratio
for kidney disease screening [24]. The results of the
current study question the use of the urine dipstick as
screening tool for low-level proteinuria in HIV patients.
Although dipstick testing would decrease costs, it would
fail to diagnose most patients with microalbuminuria, an
early marker of glomerular injury. Therefore, HIV +
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microalbuminuria. The Infectious Diseases Society of
America (IDSA) guidelines that recommend using the
dipstick as a screening tool may need to be revisited and
updated.
Limitations of the study
It is a cross-sectional study of consecutively recruited
patients with a single measurement (serum creatinine
and proteinuria) and a relatively small sample size, thus
limiting the generalization of the results to the entire
population of patients living with AIDS. In addition, pa-
tients naive to ART were also underrepresented limiting
the generalization of results obtained.
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